ShareSpot

HIV Meds Update: Treatment as Prevention: Suppressive ART, Condomless Sex, and HIV Transmission Risk - also a Word on HPTN 052

The PARTNER Study, a multisite European study, evaluated rates of HIV transmissions within serodifferent heterosexual and MSM couples (n = 548 and n = 340, respectively, contributed eligible data). The HIV-positive partners were on ART with HIV RNA levels of <200 copies/mL, and the couples engage...

HIV and Heart Disease – NIH Explores the Connection

HIV-positive men and women can now live longer than ever before. A 2013 study found that a newly diagnosed 20 year old on effective antiretroviral therapy (ART) can expect to live into their 70s. A lifespan only slightly lower than in people without HIV.[1] While this is great news, physicians are l...

Sarah
Read
National Institutes of Health
Karin
Klingman
National Institutes of Health

Accessibility: The Bigger Picture

I have been working on website accessibility for many years in my role as Production Manager at the UCSF Center for HIV Information. Despite that experience, I still encounter problems that confound me. I recently reached out to an accessibility expert for ideas on how to manage a particularly diffi...

Tips for Successful Linkage to Care

I joined the AETC National Coordinating Resource Center (NCRC) as a Health Educator in December 2015, using my skill set as a Certified Health Educator Specialist and seasoned patient navigator/linkage to care coordinator (LTCC) to provide a perspective based on direct interaction and delivery of ca...

Using Fellowships to Impact HIV Workforce Deficits

A critical shortage of practitioners who treat HIV/AIDS patients in the United States is on the horizon. According the American Academy of HIV Medicine 32% of today’s HIV clinicians will stop providing care over the next 10 years. Nearly one-third of today’s workforce will retire leaving a shortage...

Cobicistat and Stribild Use in Patients with Renal Insufficiency

Co-Author: Susa Coffey, MD; Medical Editor, AETC National Resource Center

An open-label study is evaluating the renal safety of elvitegravir/cobicistat/emtricitabine/tenofovir (Stribild, or the "quad" pill) and cobicistat. For those patients with mild-to-moderate renal impairment (estimated glomerula...

Ian
McNicholl